This report provides an updated overview on the progress of national COVID-19 vaccination strategies and deployment in European Union/European Economic Area (EU/EEA) countries, including updates on overall vaccine uptake and uptake by target group and vaccination strategies and policies.
This protocol presents a common methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating EU/EEA Member States.
This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with Severe Acute Respiratory Infection (SARI), already published as version 1.0.
This document reports on one of ECDC’s multi-country studies in the hospital setting to measure product-specific COVID-19 VE against any laboratory-confirmed SARS-CoV-2 infection among healthcare workers (HCWs) eligible for vaccination.
This pilot protocol is primarily intended to guide the implementation of a first pilot ECDC-funded study using routinely collected data, and includes a concise overview of the systems of the countries included in the pilot study.
The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) have issued a joint statement (link) providing updated public health considerations on the use of the newly authorised adapted COVID-19 vaccines to support the planning of the autumn and winter vaccination campaigns.